Early Use of Norepinephrine for Sepsis: Promising Results That Require Confirmation

Abstract

1. Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GP, Szulcek R, et al. Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med 2019;200:910–920. 2. Piquereau J, Boet A, Péchoux C, Antigny F, Lambert M, Gressette M, et al. The BET bromodomain inhibitor I-BET-151 induces structural and functional alterations of the heart mitochondria in healthy male mice and rats. Int J Mol Sci 2019;20:1527. 3. Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C, et al. Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs 2018;18:109–115.